Date: May 9, 2017 03:00 PM - 04:00 PM
Registration closes on May 15, 2017 02:45 PM
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict. The existence of relationships does not necessarily imply bias or lessen the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers. The relevant commercial financial relationships or affiliations must have occured over the past 12 months.
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of completing the activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity. Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
Requirements for CE Credit
Registration closes on May 15, 2017
at 02:45 PM
- Describe the significant outcomes associated with the selected journal article (e.g. clinical, economic, humanistic etc.)..
- Discuss the pharmacokinetics and dynamics of psilocybin and other hallucinogens and their history in medical research.
- Explain the importance of the outcomes of the selected journal article and provide context for potential use in palliative care.
Benjamin S. Kematick, Pharm.D.
Brief Bio : Dr. Kematick received his Pharm.D. from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. He completed his PGY1 Residency at the University at Buffalo - Mobile Pharmacy Solution before proceeding to his current position as a PGY2 Resident in pain Management and Palliative Care. Dr. Kematick is a current member of the Society of Palliative Care Pharmacists.
Disclosure : Dr. Kematick has completed and submitted the SIUE School of Pharmacy Continuing Pharmacy Education Form for Disclosure of Potential Conflicts of Interest and none were reported.